Gamma-crystallin A (CRYGA)

Gamma-crystallin A is a highly stable, soluble, monomeric structural protein predominantly expressed in the vertebrate eye lens, where it plays a critical role in maintaining the transparency and refractive index of the lens[1][3][7][8]. Mammalian gamma-crystallins, including Gamma-crystallin A, belong to the beta/gamma-crystallin superfamily, characterized by a two-domain beta-structure folded into four Greek key motifs and lacking connecting peptides or terminal extensions[6][8]. CRYGA is synthesized during lens fiber cell differentiation and is retained throughout life due to loss of nuclei in maturing fiber cells, making it extremely long-lived and stable[1][3]. Mutations or post-translational changes to the CRYGA protein can destabilize its structure, leading to aggregation and the development of cataracts, a major cause of blindness globally[1][3][7]. Gamma-crystallin A does not function as a receptor, enzyme, transporter, or transcription factor, and is not considered a direct therapeutic target for pharmacologic intervention or drug development[3][8]. Its clinical and research importance centers on its essential role in lens biology and its involvement in cataractogenesis when mutated.

Other names

CRYGACRY-g-ACRYG1CRYG5Gamma-A-crystallinGamma-crystallin 5gamma crystallin 5gamma-crystallin Acrystallin, gamma 1gamma-crystallin 5